Shuai Wang is a Director of Biostatistics at Pfizer, specializing in late-phase clinical trials for metabolic and cardiovascular agents. A Ph. D. graduate from Boston University, she was a key team member in the successful regulatory approval of the SGLT2 inhibitor, STEGLATRO, and has extensive experience with FDA and EMA interactions.
She was a Williams Award Finalist during her pre-doctoral studies, an honor given to only two students selected for oral presentation from over 150 abstracts.
Read the full overview →Behavioral traits and communication patterns that shape how this person evaluates opportunities, builds trust, and makes decisions in professional settings.
Dominance, influence, steadiness, and calculativeness scores with guidance on how this person prefers to communicate and decide.
Explore more public profiles from related professionals.
Discover additional public profiles from our index.
Looking for someone else? Search here for anyone.